<DOC>
	<DOC>NCT03006926</DOC>
	<brief_summary>This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC).</brief_summary>
	<brief_title>A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Confirmed diagnosis of hepatocellular carcinoma (HCC) HCC for which no other appropriate therapy is available. Note: Expansion Part: No prior systemic therapy for advanced/unresectable HCC Stage B (not applicable for transarterial chemoembolization [TACE]), or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system At least 1 measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) ChildPugh score A Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1 Adequately controlled blood pressure Adequate renal function Adequate bone marrow function Adequate blood coagulation function Adequate liver function Males or females age â‰¥ 18 years at the time of informed consent Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol Prior treatment with lenvatinib or any antiPD1, antiPDL1, or antiPDL2 agent Any current brain or subdural metastases Active malignancy (except for HCC or definitively treated melanoma insitu, basal or squamous cell carcinoma of the skin, or carcinoma insitu of the cervix) within the past 36 months Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>E7080</keyword>
	<keyword>lenvatinib</keyword>
	<keyword>pembrolizumab</keyword>
	<keyword>Japan</keyword>
</DOC>